In NSCLC patients, the proportion of PD-1T cells among responders to PD-1 blockade therapy was significantly greater than that among nonresponders, and PD-1 T cells were associated with improved OS (HR 0.16 (95% CI 0.05–0.52),p < 0.05) (27). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.